The following transcript is automatically generated and may contain typos or misspellings. Please listen to the episode for the most accurate language. Dr. Susan Manzi 0:00 Hello everyone. I'm Dr.
Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in systemic lupus erythematosus.
The American College of Rheumatology (ACR) has released a summary of a guideline with updated recommendations for the treatment of systemic lupus erythematosus (SLE). The previous guideline for ...
Telitacicept, a dual inhibitor of the cytokines B-lymphocyte stimulator and a proliferation-inducing ligand, showed efficacy ...
Objectives The European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of systemic lupus erythematosus (SLE) and lupus nephritis provide important guidance for ...
The study is aimed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), preliminary efficacy and biomarkers of orelabrutinib in patients with mild to moderate SLE who ...
Belimumab demonstrates notable efficacy for enhancing treatment outcomes among adults with active systemic lupus erythematosus when added to standard therapy. Belimumab demonstrates notable efficacy ...
As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive ...
A Phase II study was subsequently performed by the LBSL02/99 group, which enrolled 449 patients who met American College of Rheumatology (ACR) diagnostic criteria for SLE, had active SLE disease and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback